QQQ   283.85 (+1.18%)
AAPL   142.65 (+1.21%)
MSFT   247.40 (+1.24%)
META   115.33 (+1.23%)
GOOGL   93.71 (-1.30%)
AMZN   90.35 (+2.14%)
TSLA   173.44 (-0.34%)
NVDA   171.69 (+6.51%)
NIO   13.41 (+6.60%)
BABA   94.17 (+6.61%)
AMD   70.47 (+0.47%)
T   19.12 (-0.93%)
MU   55.20 (+2.56%)
CGC   3.09 (-4.63%)
F   13.12 (+0.15%)
GE   83.63 (-1.61%)
DIS   92.55 (+0.43%)
AMC   6.07 (+0.33%)
PYPL   74.22 (-0.27%)
PFE   51.78 (+3.07%)
NFLX   310.26 (+0.60%)
QQQ   283.85 (+1.18%)
AAPL   142.65 (+1.21%)
MSFT   247.40 (+1.24%)
META   115.33 (+1.23%)
GOOGL   93.71 (-1.30%)
AMZN   90.35 (+2.14%)
TSLA   173.44 (-0.34%)
NVDA   171.69 (+6.51%)
NIO   13.41 (+6.60%)
BABA   94.17 (+6.61%)
AMD   70.47 (+0.47%)
T   19.12 (-0.93%)
MU   55.20 (+2.56%)
CGC   3.09 (-4.63%)
F   13.12 (+0.15%)
GE   83.63 (-1.61%)
DIS   92.55 (+0.43%)
AMC   6.07 (+0.33%)
PYPL   74.22 (-0.27%)
PFE   51.78 (+3.07%)
NFLX   310.26 (+0.60%)
QQQ   283.85 (+1.18%)
AAPL   142.65 (+1.21%)
MSFT   247.40 (+1.24%)
META   115.33 (+1.23%)
GOOGL   93.71 (-1.30%)
AMZN   90.35 (+2.14%)
TSLA   173.44 (-0.34%)
NVDA   171.69 (+6.51%)
NIO   13.41 (+6.60%)
BABA   94.17 (+6.61%)
AMD   70.47 (+0.47%)
T   19.12 (-0.93%)
MU   55.20 (+2.56%)
CGC   3.09 (-4.63%)
F   13.12 (+0.15%)
GE   83.63 (-1.61%)
DIS   92.55 (+0.43%)
AMC   6.07 (+0.33%)
PYPL   74.22 (-0.27%)
PFE   51.78 (+3.07%)
NFLX   310.26 (+0.60%)
QQQ   283.85 (+1.18%)
AAPL   142.65 (+1.21%)
MSFT   247.40 (+1.24%)
META   115.33 (+1.23%)
GOOGL   93.71 (-1.30%)
AMZN   90.35 (+2.14%)
TSLA   173.44 (-0.34%)
NVDA   171.69 (+6.51%)
NIO   13.41 (+6.60%)
BABA   94.17 (+6.61%)
AMD   70.47 (+0.47%)
T   19.12 (-0.93%)
MU   55.20 (+2.56%)
CGC   3.09 (-4.63%)
F   13.12 (+0.15%)
GE   83.63 (-1.61%)
DIS   92.55 (+0.43%)
AMC   6.07 (+0.33%)
PYPL   74.22 (-0.27%)
PFE   51.78 (+3.07%)
NFLX   310.26 (+0.60%)
NASDAQ:SLDB

Solid Biosciences - SLDB Stock Forecast, Price & News

$6.48
-0.12 (-1.82%)
(As of 12/8/2022 12:00 AM ET)
Add
Compare
Today's Range
$6.36
$6.75
50-Day Range
$6.11
$91.65
52-Week Range
$5.89
$30.45
Volume
27,885 shs
Average Volume
47,714 shs
Market Capitalization
$48.83 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$45.00

Solid Biosciences MarketRank™ Forecast

Analyst Rating
Hold
2.25 Rating Score
Upside/​Downside
594.4% Upside
$45.00 Price Target
Short Interest
Healthy
1.75% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.24mentions of Solid Biosciences in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($11.63) to ($6.00) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.25 out of 5 stars

Medical Sector

336th out of 1,022 stocks

Biological Products, Except Diagnostic Industry

54th out of 171 stocks

SLDB stock logo

About Solid Biosciences (NASDAQ:SLDB) Stock

Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

Receive SLDB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Solid Biosciences and its competitors with MarketBeat's FREE daily newsletter.

SLDB Stock News Headlines

Solid Biosciences Inc. (NASDAQ:SLDB) Short Interest Update
Solid Biosciences reports Q3 results
Techne (TECH) Lags Q1 Earnings and Revenue Estimates
Solid Biosciences Announces a 1-for-15 Reverse Stock Split
Solid Biosciences Stock Rises on Merger with AavantiBio
Solid Biosciences Inc. (SLDB)
See More Headlines
Receive SLDB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Solid Biosciences and its competitors with MarketBeat's FREE daily newsletter.

SLDB Company Calendar

Last Earnings
11/10/2022
Today
12/08/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/13/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SLDB
Fax
N/A
Employees
104
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$45.00
High Stock Price Forecast
$90.00
Low Stock Price Forecast
$15.00
Forecasted Upside/Downside
+594.4%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
4 Analysts

Profitability

Net Income
$-72,190,000.00
Net Margins
-588.52%
Pretax Margin
-795.16%

Debt

Sales & Book Value

Annual Sales
$13.62 million
Book Value
$28.30 per share

Miscellaneous

Free Float
6,421,000
Market Cap
$48.83 million
Optionable
Optionable
Beta
1.37

Key Executives

  • Mr. Ian F. Smith A.C.A. (Age 56)
    ACA, C.P.A., CPA, Exec. Chair
    Comp: $72.73k
  • Mr. Ilan Ganot (Age 48)
    Co-founder, Pres, CEO & Director
    Comp: $749.03k
  • Mr. Matthew Bennett Arnold (Age 52)
    Co-Founder & Board Member
    Comp: $19.45k
  • Ms. Erin Powers Brennan (Age 51)
    Chief Legal Officer & Sec.
    Comp: $495.99k
  • Mr. Gilad David Hayeem (Age 54)
    Co-Founder
  • Ms. Annie Ganot
    Co-Founder & Head of Patient Advocacy
  • Dr. Andrey Juan Zarur Ph.D. (Age 51)
    Co-Founder
  • Mr. Stephen J. Di Palma M.B.A (Age 63)
    M.B.A., Interim CFO, Treasurer & Principal Accounting Officer
  • Dr. Carl Ashley Morris Ph.D.Dr. Carl Ashley Morris Ph.D. (Age 52)
    Chief Scientific Officer
  • Ms. Caitlin Lowie
    VP of Communications & IR













SLDB Stock - Frequently Asked Questions

Should I buy or sell Solid Biosciences stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Solid Biosciences in the last year. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" SLDB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SLDB, but not buy additional shares or sell existing shares.
View SLDB analyst ratings
or view top-rated stocks.

What is Solid Biosciences' stock price forecast for 2023?

4 Wall Street research analysts have issued 12-month price targets for Solid Biosciences' stock. Their SLDB share price forecasts range from $15.00 to $90.00. On average, they predict the company's share price to reach $45.00 in the next year. This suggests a possible upside of 594.4% from the stock's current price.
View analysts price targets for SLDB
or view top-rated stocks among Wall Street analysts.

How have SLDB shares performed in 2022?

Solid Biosciences' stock was trading at $26.25 at the beginning of the year. Since then, SLDB shares have decreased by 75.3% and is now trading at $6.48.
View the best growth stocks for 2022 here
.

Are investors shorting Solid Biosciences?

Solid Biosciences saw a increase in short interest in November. As of November 15th, there was short interest totaling 110,400 shares, an increase of 69.1% from the October 31st total of 65,300 shares. Based on an average trading volume of 30,000 shares, the days-to-cover ratio is currently 3.7 days. Currently, 1.8% of the shares of the stock are short sold.
View Solid Biosciences' Short Interest
.

When is Solid Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 13th 2023.
View our SLDB earnings forecast
.

How were Solid Biosciences' earnings last quarter?

Solid Biosciences Inc. (NASDAQ:SLDB) announced its quarterly earnings data on Thursday, November, 10th. The company reported ($2.71) EPS for the quarter, missing the consensus estimate of ($2.59) by $0.12. Solid Biosciences had a negative trailing twelve-month return on equity of 51.17% and a negative net margin of 588.52%.

When did Solid Biosciences' stock split?

Shares of Solid Biosciences reverse split on the morning of Friday, October 28th 2022. The 1-15 reverse split was announced on Friday, October 28th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, October 28th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Solid Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Solid Biosciences investors own include Selecta Biosciences (SELB), VBI Vaccines (VBIV), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Amarin (AMRN), Catalyst Pharmaceuticals (CPRX), Cidara Therapeutics (CDTX), SCYNEXIS (SCYX), Verastem (VSTM) and Agile Therapeutics (AGRX).

When did Solid Biosciences IPO?

(SLDB) raised $130 million in an IPO on Friday, January 26th 2018. The company issued 7,000,000 shares at $18.00-$19.00 per share. J.P. Morgan, Goldman Sachs and Leerink Partners acted as the underwriters for the IPO and Nomura and Chardan were co-managers.

What is Solid Biosciences' stock symbol?

Solid Biosciences trades on the NASDAQ under the ticker symbol "SLDB."

Who are Solid Biosciences' major shareholders?

Solid Biosciences' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (44.32%), BlackRock Inc. (37.69%), Renaissance Technologies LLC (13.43%), Ergoteles LLC (2.71%), Two Sigma Advisers LP (2.48%) and Group One Trading L.P. (0.00%). Insiders that own company stock include Carl Ashley Morris, Ilan Ganot, Jennifer Lynn Ziolkowski, Joel Solomon Zev Schneider, Perceptive Advisors Llc and Ra Capital Management, LP.
View institutional ownership trends
.

How do I buy shares of Solid Biosciences?

Shares of SLDB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Solid Biosciences' stock price today?

One share of SLDB stock can currently be purchased for approximately $6.48.

How much money does Solid Biosciences make?

Solid Biosciences (NASDAQ:SLDB) has a market capitalization of $48.83 million and generates $13.62 million in revenue each year. The company earns $-72,190,000.00 in net income (profit) each year or ($11.8555) on an earnings per share basis.

How many employees does Solid Biosciences have?

The company employs 104 workers across the globe.

How can I contact Solid Biosciences?

Solid Biosciences' mailing address is 141 PORTLAND STREET FIFTH FLOOR, CAMBRIDGE MA, 02139. The official website for the company is www.solidbio.com. The company can be reached via phone at (617) 337-4680.

This page (NASDAQ:SLDB) was last updated on 12/8/2022 by MarketBeat.com Staff